Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash-to-Debt No Debt
GKOS's Cash-to-Debt is ranked higher than
81% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.62 vs. GKOS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
GKOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.12  Med: 4.89 Max: No Debt
Current: No Debt
Equity-to-Asset 0.87
GKOS's Equity-to-Asset is ranked higher than
91% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.58 vs. GKOS: 0.87 )
Ranked among companies with meaningful Equity-to-Asset only.
GKOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -5.81  Med: -1.88 Max: 0.87
Current: 0.87
-5.81
0.87
Interest Coverage 6.98
GKOS's Interest Coverage is ranked lower than
79% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 45.06 vs. GKOS: 6.98 )
Ranked among companies with meaningful Interest Coverage only.
GKOS' s Interest Coverage Range Over the Past 10 Years
Min: 6.98  Med: 5002.99 Max: N/A
Current: 6.98
Piotroski F-Score: 7
Altman Z-Score: 61.53
Beneish M-Score: -2.05
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 3.71
GKOS's Operating Margin % is ranked lower than
53% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.86 vs. GKOS: 3.71 )
Ranked among companies with meaningful Operating Margin % only.
GKOS' s Operating Margin % Range Over the Past 10 Years
Min: -67.78  Med: -21.63 Max: 3.71
Current: 3.71
-67.78
3.71
Net Margin % 3.95
GKOS's Net Margin % is ranked higher than
51% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.79 vs. GKOS: 3.95 )
Ranked among companies with meaningful Net Margin % only.
GKOS' s Net Margin % Range Over the Past 10 Years
Min: -60.34  Med: -39.27 Max: 3.95
Current: 3.95
-60.34
3.95
ROE % 4.30
GKOS's ROE % is ranked higher than
50% of the 182 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.30 vs. GKOS: 4.30 )
Ranked among companies with meaningful ROE % only.
GKOS' s ROE % Range Over the Past 10 Years
Min: 4.26  Med: 4.26 Max: 4.3
Current: 4.3
4.26
4.3
ROA % 3.64
GKOS's ROA % is ranked higher than
58% of the 191 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.23 vs. GKOS: 3.64 )
Ranked among companies with meaningful ROA % only.
GKOS' s ROA % Range Over the Past 10 Years
Min: -52.2  Med: -41.78 Max: 3.64
Current: 3.64
-52.2
3.64
ROC (Joel Greenblatt) % 44.97
GKOS's ROC (Joel Greenblatt) % is ranked higher than
82% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.88 vs. GKOS: 44.97 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
GKOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -760.88  Med: -526.13 Max: 45.47
Current: 44.97
-760.88
45.47
GuruFocus has detected 2 Warning Signs with Glaukos Corp $GKOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» GKOS's 10-Y Financials

Financials (Next Earnings Date: 2017-06-01 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

GKOS Guru Trades in Q1 2016

Ron Baron 23,925 sh (-42.14%)
» More
Q2 2016

GKOS Guru Trades in Q2 2016

Jim Simons 124,400 sh (New)
Steven Cohen 264,200 sh (New)
Ron Baron 23,925 sh (unchged)
» More
Q3 2016

GKOS Guru Trades in Q3 2016

Paul Tudor Jones 7,300 sh (New)
Jim Simons 705,200 sh (+466.88%)
Ron Baron 115,261 sh (+381.76%)
Steven Cohen 142,600 sh (-46.03%)
» More
Q4 2016

GKOS Guru Trades in Q4 2016

Ron Baron 530,365 sh (+360.14%)
Steven Cohen 364,300 sh (+155.47%)
Jim Simons 849,000 sh (+20.39%)
Paul Tudor Jones Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GKOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:MMSI, NYSE:HYH, OTCPK:TOPCF, NAS:NXTM, NYSE:HAE, NAS:NVCR, NAS:ATRI, NAS:LMNX, NAS:IRTC, NAS:OSUR, NAS:PODD, OTCPK:NNCSF, NAS:ATRC, OTCPK:ANSLF, NAS:ELGX, NAS:ANGO, NAS:LMAT, NAS:MLAB, NAS:ATRS, OTCPK:GMDTF » details
Traded in other countries:6GJ.Germany,
Headquarter Location:USA
Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Glaukos Corp was incorporated in Delaware on July 14, 1998. The Company is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. The Company launched the iStent, the first MIGS device, in the United States in July 2012. It is building a portfolio of micro-scale injectable therapies designed to address the complete range of glaucoma disease states and progression, including three pipeline products: the iStent Inject, the iStent Supra and iDose. The iStent Inject includes two stents pre-loaded in an auto-injection inserter. It is developing two versions of this product: the first is currently being studied for lowering intraocular pressure in conjunction with cataract surgery in a U.S. investigational device exemption, or IDE, pivotal trial; the second is currently being studied in an initial U.S. IDE study as a standalone treatment for lowering intraocular pressure. This second version is also capable of making its own self-sealing corneal penetration, potentially offering patient treatment in a minor surgical suite or an in-office setting. The iStent Supra is designed to access an alternative drainage space within the eye where in aqueous humor outflow occurs, and is now in a U.S. pivotal IDE trial. iDose is an implant that is designed to provide a sustained release of a prostaglandin drug to lower intraocular pressure in glaucoma patients. In the United States, it sells its products through a direct sales organization. Outside the United States, it sells its products through a network of distribution partners located in markets where it sees the greatest potential for iStent adoption. It manufactures, inspects, packages and ships finished products from its Laguna Hills facility. Companies with competing products include Alcon, Inc., Abbott Medical Optics Inc., STAAR Surgical Company, Lumenis Ltd., NeoMedix,Inc. and Ellex Medical Lasers Limited. Alcon, Inc. and Abbott Medical Optics Inc. are the manufacturers of aqueous shunts, and Alcon, Inc. also markets the EX-PRESS Glaucoma Filtration Device. Lumenis Ltd. is a manufacturer of SLT equipment. Neomedix, Inc. markets an electrosurgical device and Ellex Medical Lasers Limited markets a canaloplasty device that some physicians employ to lower intraocular pressure in glaucoma. The Company owns or exclusively licenses in certain fields of use issued patents, of which owned that were issued in the United States and that were issued outside of the United States, and pending patent applications, of which it owns that were filed in the United States and 19 that were filed outside of the United States. Its trademark includes Glaukos, iStent, iStent Inject, iStent Supra, iDose, MIGS and other marks. The Company is subject to a variety of federal, state and local regulations relating to the use, handling, storage, disposal, and human exposure to hazardous and toxic ma

Guru Investment Theses on Glaukos Corp

Baron Opportunity Fund Comments on Glaukos Corp - Apr 20, 2017

Shares of Glaukos Corporation (NYSE:GKOS), a pioneer of minimally-invasive products and procedures for the treatment of glaucoma, were up in the first quarter due to strong financial results that beat Street expectations, with revenues growing 64%. The company also raised 2017 guidance and announced favorable Medicare reimbursement. Glaukos’ products and procedures are currently approved for only a subset of the market. We believe the company will continue to deliver strong growth as its product coverage broadens. (Josh Riegelhaupt)



From the Baron Opportunity Fund first quarter 2017 shareholder letter.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corporation - Jan 18, 2017

High growth These are higher risk/return companies typified by revenue growth of 20% or more that we believe will lead to dramatic earnings growth in the future. This category includes newer businesses with novel products or services. Yet these companies are not venture businesses. An example is Glaukos Corporation (NYSE:GKOS), a medical device company that sells a stent used to treat glaucoma, a disease that damages the optic nerve due to fluid buildup inside the eye. Glaukos’ first generation device, which is inserted into the eye during cataract surgery, has been proven to decrease intraocular pressure. Glaukos also has a promising product pipeline that includes next generation stents for stand-alone glaucoma procedures and an injectable drug delivery implant. The company has a two-year lead over its competitors, patent protection, and strong clinical data. We believe the addressable market exceeds $5 billion.





From Baron Discovery Fund's Investing in Earlier Stage Small Cap Growth Companies January 2017.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corp - Oct 25, 2016

Glaukos Corporation (NYSE:GKOS) is the current market leader in the field of minimally-invasive glaucoma surgery or MIGS. As a pioneer in the field, Glaukos was the first to obtain FDA approval and insurance reimbursement for their eye stent, which they cleverly branded the iStent. Given the progressive nature of glaucoma that inevitably leads to blindness unless one’s eye pressure is effectively controlled, the iStent offers ophthalmologists a paradigm-shifting treatment option. Effectively, the iStent is a micro-sized plumbing solution that clears a blocked drain enabling a return of proper fluid flow. This allows for continuous pressure control and, as an ancillary benefit, a reduction in the need for concomitant glaucoma eye drops.







From Baron Opportunity Fund third-quarter 2016 commentary.



Check out Ron Baron latest stock trades

Baron Funds Comments on Glaukos Corporation - May 19, 2016

Shares of Glaukos Corporation (NYSE:GKOS) declined in the first quarter as a result of the massive correction in the biotech/pharma space. Glaukos, which manufactures stents to relieve glaucoma pressure, expects 26% to 30% growth in 2016, which we think will drive revenue to $90 millin to $93 million. While major label expansion to deliver Glaukos’ iStents without cataract surgery (current FDA approval) is still some years away, we retain conviction because of the growth opportunity presented by the rising incidence of glaucoma as a result of the aging U.S. population.



From the Baron Global Advantage Fund first quarter 2016 commentary.



Check out Ron Baron latest stock trades

Top Ranked Articles about Glaukos Corp

Baron Opportunity Fund Comments on Glaukos Corp Guru stock highlight
Shares of Glaukos Corporation (NYSE:GKOS), a pioneer of minimally-invasive products and procedures for the treatment of glaucoma, were up in the first quarter due to strong financial results that beat Street expectations, with revenues growing 64%. The company also raised 2017 guidance and announced favorable Medicare reimbursement. Glaukos’ products and procedures are currently approved for only a subset of the market. We believe the company will continue to deliver strong growth as its product coverage broadens. (Josh Riegelhaupt) Read more...
Baron Funds Comments on Glaukos Corporation Guru stock highlight
High growth These are higher risk/return companies typified by revenue growth of 20% or more that we believe will lead to dramatic earnings growth in the future. This category includes newer businesses with novel products or services. Yet these companies are not venture businesses. An example is Glaukos Corporation (NYSE:GKOS), a medical device company that sells a stent used to treat glaucoma, a disease that damages the optic nerve due to fluid buildup inside the eye. Glaukos’ first generation device, which is inserted into the eye during cataract surgery, has been proven to decrease intraocular pressure. Glaukos also has a promising product pipeline that includes next generation stents for stand-alone glaucoma procedures and an injectable drug delivery implant. The company has a two-year lead over its competitors, patent protection, and strong clinical data. We believe the addressable market exceeds $5 billion. Read more...
Baron Funds Comments on Glaukos Corp Guru stock highlight
Glaukos Corporation (NYSE:GKOS) is the current market leader in the field of minimally-invasive glaucoma surgery or MIGS. As a pioneer in the field, Glaukos was the first to obtain FDA approval and insurance reimbursement for their eye stent, which they cleverly branded the iStent. Given the progressive nature of glaucoma that inevitably leads to blindness unless one’s eye pressure is effectively controlled, the iStent offers ophthalmologists a paradigm-shifting treatment option. Effectively, the iStent is a micro-sized plumbing solution that clears a blocked drain enabling a return of proper fluid flow. This allows for continuous pressure control and, as an ancillary benefit, a reduction in the need for concomitant glaucoma eye drops. Read more...
CEO of Glaukos Trades Portion of Stake in Company Thomas Burns sells 162,254 shares for more than $4.8 million
Thomas Burns (Insider Trades), CEO of Glaukos Corp. (GKOS), sold 162,254 shares for $30.07 per share on July 13 for a total transaction of $4,878,978. Read more...
Weekly CEO Sells Highlights Insiders trade shares in PepsiCo, Glaukos, Blue Buffalo Pet Products, PGT
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: PepsiCo Inc. (NYSE:PEP), Glaukos Corp. (NYSE:GKOS), Blue Buffalo Pet Products Inc. (NASDAQ:BUFF) and PGT Inc. (NYSE:PGTI). Read more...
Baron Funds Comments on Glaukos Corporation Guru stock highlight
Shares of Glaukos Corporation (NYSE:GKOS) declined in the first quarter as a result of the massive correction in the biotech/pharma space. Glaukos, which manufactures stents to relieve glaucoma pressure, expects 26% to 30% growth in 2016, which we think will drive revenue to $90 millin to $93 million. While major label expansion to deliver Glaukos’ iStents without cataract surgery (current FDA approval) is still some years away, we retain conviction because of the growth opportunity presented by the rising incidence of glaucoma as a result of the aging U.S. population. Read more...

Ratios

vs
industry
vs
history
PE Ratio 61.69
GKOS's PE Ratio is ranked lower than
86% of the 118 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.48 vs. GKOS: 61.69 )
Ranked among companies with meaningful PE Ratio only.
GKOS' s PE Ratio Range Over the Past 10 Years
Min: 37.03  Med: 50.84 Max: 429.17
Current: 61.69
37.03
429.17
Forward PE Ratio 370.37
GKOS's Forward PE Ratio is ranked lower than
100% of the 78 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.42 vs. GKOS: 370.37 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 365.62
GKOS's PE Ratio without NRI is ranked lower than
99% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.38 vs. GKOS: 365.62 )
Ranked among companies with meaningful PE Ratio without NRI only.
GKOS' s PE Ratio without NRI Range Over the Past 10 Years
Min: 37.03  Med: 50.84 Max: 396.15
Current: 365.62
37.03
396.15
PB Ratio 13.72
GKOS's PB Ratio is ranked lower than
94% of the 181 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.56 vs. GKOS: 13.72 )
Ranked among companies with meaningful PB Ratio only.
GKOS' s PB Ratio Range Over the Past 10 Years
Min: 5.19  Med: 9.41 Max: 14.91
Current: 13.72
5.19
14.91
PS Ratio 15.12
GKOS's PS Ratio is ranked lower than
93% of the 180 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.01 vs. GKOS: 15.12 )
Ranked among companies with meaningful PS Ratio only.
GKOS' s PS Ratio Range Over the Past 10 Years
Min: 1.84  Med: 4.51 Max: 16.38
Current: 15.12
1.84
16.38
Price-to-Free-Cash-Flow 286.35
GKOS's Price-to-Free-Cash-Flow is ranked lower than
97% of the 73 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 29.88 vs. GKOS: 286.35 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
GKOS' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 193.01  Med: 412.05 Max: 1165.33
Current: 286.35
193.01
1165.33
Price-to-Operating-Cash-Flow 141.02
GKOS's Price-to-Operating-Cash-Flow is ranked lower than
95% of the 95 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 19.90 vs. GKOS: 141.02 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
GKOS' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 95.07  Med: 152.57 Max: 384.18
Current: 141.02
95.07
384.18
EV-to-EBIT 408.50
GKOS's EV-to-EBIT is ranked lower than
99% of the 194 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 24.30 vs. GKOS: 408.50 )
Ranked among companies with meaningful EV-to-EBIT only.
GKOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -1191.8  Med: -20.2 Max: 768.6
Current: 408.5
-1191.8
768.6
EV-to-EBITDA 193.24
GKOS's EV-to-EBITDA is ranked lower than
99% of the 203 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.15 vs. GKOS: 193.24 )
Ranked among companies with meaningful EV-to-EBITDA only.
GKOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.2  Med: 0.2 Max: 346.8
Current: 193.24
-189.2
346.8
Current Ratio 7.09
GKOS's Current Ratio is ranked higher than
90% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.54 vs. GKOS: 7.09 )
Ranked among companies with meaningful Current Ratio only.
GKOS' s Current Ratio Range Over the Past 10 Years
Min: 0.52  Med: 3.65 Max: 7.09
Current: 7.09
0.52
7.09
Quick Ratio 6.68
GKOS's Quick Ratio is ranked higher than
90% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.67 vs. GKOS: 6.68 )
Ranked among companies with meaningful Quick Ratio only.
GKOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.41  Med: 3.38 Max: 6.68
Current: 6.68
0.41
6.68
Days Inventory 126.20
GKOS's Days Inventory is ranked lower than
51% of the 175 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 124.79 vs. GKOS: 126.20 )
Ranked among companies with meaningful Days Inventory only.
GKOS' s Days Inventory Range Over the Past 10 Years
Min: 65.71  Med: 106.37 Max: 266.8
Current: 126.2
65.71
266.8
Days Sales Outstanding 45.64
GKOS's Days Sales Outstanding is ranked higher than
82% of the 153 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.76 vs. GKOS: 45.64 )
Ranked among companies with meaningful Days Sales Outstanding only.
GKOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 38.43  Med: 44.43 Max: 50.4
Current: 45.64
38.43
50.4
Days Payable 66.94
GKOS's Days Payable is ranked higher than
59% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 53.53 vs. GKOS: 66.94 )
Ranked among companies with meaningful Days Payable only.
GKOS' s Days Payable Range Over the Past 10 Years
Min: 66.94  Med: 103.67 Max: 480.19
Current: 66.94
66.94
480.19

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 20.49
GKOS's Price-to-Net-Cash is ranked lower than
60% of the 48 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 17.17 vs. GKOS: 20.49 )
Ranked among companies with meaningful Price-to-Net-Cash only.
GKOS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 11.43  Med: 13.11 Max: 20.65
Current: 20.49
11.43
20.65
Price-to-Net-Current-Asset-Value 15.69
GKOS's Price-to-Net-Current-Asset-Value is ranked lower than
79% of the 109 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.18 vs. GKOS: 15.69 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
GKOS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 9.61  Med: 10.47 Max: 15.81
Current: 15.69
9.61
15.81
Price-to-Tangible-Book 14.58
GKOS's Price-to-Tangible-Book is ranked lower than
89% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.77 vs. GKOS: 14.58 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
GKOS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 9.35  Med: 9.94 Max: 14.7
Current: 14.58
9.35
14.7
Price-to-Median-PS-Value 3.35
GKOS's Price-to-Median-PS-Value is ranked lower than
97% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.14 vs. GKOS: 3.35 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
GKOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.66  Med: 1.54 Max: 3.38
Current: 3.35
0.66
3.38
Price-to-Graham-Number 15.38
GKOS's Price-to-Graham-Number is ranked lower than
98% of the 87 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.67 vs. GKOS: 15.38 )
Ranked among companies with meaningful Price-to-Graham-Number only.
GKOS' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 11.55  Med: 11.55 Max: 15.5
Current: 15.38
11.55
15.5
Earnings Yield (Greenblatt) % 0.26
GKOS's Earnings Yield (Greenblatt) % is ranked lower than
67% of the 267 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.18 vs. GKOS: 0.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
GKOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.1  Med: 0.3 Max: 952.5
Current: 0.26
0.1
952.5

More Statistics

Revenue (TTM) (Mil) $114.4
EPS (TTM) $ 0.77
Short Percentage of Float7.81%
52-Week Range $18.39 - 52.49
Shares Outstanding (Mil)34.28

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 160 201
EPS ($) 0.13 0.34
EPS without NRI ($) 0.13 0.34
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for GKOS

Headlines

Articles On GuruFocus.com
Baron Opportunity Fund Comments on Glaukos Corp Apr 20 2017 
Baron Opportunity Fund First Quarter 2017 Shareholder Letter Apr 20 2017 
Baron Funds Comments on Glaukos Corporation Jan 18 2017 
Investing in Earlier Stage Small Cap Growth Companies - Baron Discovery Fund Jan 18 2017 
Baron Funds Comments on Glaukos Corp Oct 25 2016 
CEO of Glaukos Trades Portion of Stake in Company Jul 15 2016 
Weekly CEO Sells Highlights Jul 15 2016 
Baron Funds Comments on Glaukos Corporation May 19 2016 

More From Other Websites
Glaukos Corp. breached its 50 day moving average in a Bullish Manner : GKOS-US : April 28, 2017 Apr 28 2017
Cerner (CERN) Earnings and Revenues Beat Estimates in Q1 Apr 28 2017
CONMED (CNMD) Q1 Earnings Surpass Estimates, Increase Y/Y Apr 27 2017
Glaukos Corporation to Release First Quarter 2017 Financial Results after Market Close on May 3 Apr 19 2017
Glaukos Corp. breached its 50 day moving average in a Bearish Manner : GKOS-US : April 14, 2017 Apr 14 2017
Why Apogee Enterprises, Embraer, and Glaukos Slumped Today Apr 13 2017
Glaukos Dives To 1-Month Low On Proposal To Slash Reimbursements Apr 13 2017
International Study Shows Two Glaukos iStent® Trabecular Micro-Bypass Stents and One Topical... Apr 13 2017
Glaukos Corporation Acquires IOP Sensor System from DOSE Medical Apr 12 2017
3 Stocks That Are Overvalued Apr 10 2017
Glaukos shares risk steep decline as rivals pressure - Barron's Apr 09 2017
[$$] Skeptics Eye Potential Trouble for Glaukos Apr 07 2017
ETFs with exposure to Glaukos Corp. : April 5, 2017 Apr 05 2017
Glaukos Announces Five-Year Extensions for Three Category III CPT Codes Related to Micro-Invasive... Mar 16 2017
ETFs with exposure to Glaukos Corp. : March 6, 2017 Mar 06 2017
Glaukos Corp. :GKOS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 3, 2017 Mar 03 2017
Amedisys Stock Up on Solid Earnings, Reimbursement Woes Stay Mar 03 2017
Stocks, Dow Jones close down: Snap debuts, Caterpillar sinks after search warrants Mar 02 2017
Glaukos Stock Hits Record High On Q4 Sales Beat, Posts No Losses Mar 02 2017
Glaukos Corp. Stock Notches Gains With Eye-Popping Results Mar 02 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)